Citations

Clear

3942 citation(s) found for "To, Van".

Controversies, Consensus, and Collaboration in the Use of 131 I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medici
Tuttle, R. Michael , Ahuja, Sukhjeet, Avram, Anca M. , Bernet, Victor , Bourguet, P., Daniels, Gilbert H. , Dillehay, Gary, Draganescu, Ciprian, Flux, Glenn , Führer, Dagmar, Greenspan, Bennett S. , Luster, Markus , Muylle, Kristoff , Nostrand, Douglas Van , Verburg, Frederik A. , Hegedüs, László , Bernet, Victor J, Giovanella, Luca , Smit, Johannes W. A.

Mayo Clinic

Thyroid® | March 22, 2019 | Volume: 29 | Issue: 4 | Pages: 461-470

10.1089/thy.2018.0597 | PMID 30900516 Get It

Background: Publication of the 2015 American Thyroid Association (ATA) management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met with disagreement by the extended nuclear medicine community with regard to some of the recommendations related to the diagnostic and therapeutic use of radioiodine ( 131 I). Because of these concerns, the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging declined to endorse the ATA guidelines. As a result of these differences in opinion, patients and clinicians risk receiving conflicting advice with regard to several key thyroid cancer management issues. Summary: To address some of the differences in opinion and controversies associated with the therapeutic uses of 131 I in differentiated thyroid cancer constructively, the ATA, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association each sent senior leadership and subject-matter experts to a two-day interactive meeting. The goals of this first meeting were to (i) formalize the dialogue and activities between the four societies; (ii) discuss indications for 131 I adjuvant treatment; (iii) define the optimal prescribed activity of 131 I for adjuvant treatment; and (iv) clarify the definition and classification of 131 I-refractory thyroid cancer. Conclusion: By fostering an open, productive, and evidence-based discussion, the Martinique meeting restored trust, confidence, and a sense of collegiality between individuals and organizations that are committed to optimal thyroid disease management. The result of this first meeting is a set of nine principles (The Martinique Principles) that (i) describe a commitment to proactive, purposeful, and inclusive interdisciplinary cooperation; (ii) define the goals of 131 I therapy as remnant ablation, adjuvant treatment, or treatment of known disease; (iii) describe the importance of evaluating postoperative disease status and multiple other factors beyond clinicopathologic staging in 131 I therapy decision making; (iv) recognize that the optimal administered activity of 131 I adjuvant treatment cannot be definitely determined from the published literature; and (v) acknowledge that current definitions of 131 I-refractory disease are suboptimal and do not represent definitive criteria to mandate whether 131 I therapy should be recommended.
How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy
Grimm, Max‐Joseph, Respondek, Gesine , Stamelou, María , Arzberger, Thomas, Ferguson, Leslie W. , Gelpí, Ellen , Irwin, David J. , Pantelyat, Alexander , Rajput, Alex, Roeber, Sigrun, Troakes, Claire , Antonini, Angelo , Eimeren, Thilo van , Kassubek, Jan , Xiong, Chengjie , Meissner, Wassilios G. , Oertel, Wolfgang H. , Piot, Ines , Boxer, Adam L. , Golbe, Lawrence I. , Josephs, Keith A. , Morris, Huw R. , Whitwell, Jennifer L. , Compta, Yaroslau , Corvol, Jean‐Christophe , Rowe, James B. , Höglinger, Günter U. , Group, for the Movement Disorder Society‐endorsed PSP Study, Irwin, David J , Antonini, Angelo , Meissner, Wassilios G , Lang, Anthony E , Rowe, James B , Höglinger, Günter U , Corvol, Jean-Christophe , Xiong, Chengjie , Gelpi, Ellen , Pantelyat, Alex , Giese, Armin , Grossman, Murray , Swieten, John C. van , Bhatia, Kailash P. , Colosimo, Carlo , Nilsson, Christer, Poewe, Werner H , Wenning, Gregor K. , Litvan, Irene , Lang, Anthony E. , Group, for the Movement Disorder Society‐endorsed PSP Study, Troakes, Claire , Morris, Huw R , van Eimeren, Thilo

Mayo Clinic

Movement Disorders | March 19, 2019 | Volume: 34 | Issue: 8 | Pages: 1228-1232

10.1002/mds.27666 | PMID 30884545 Get It

Abstract Background The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy‐confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society
A Versatile Protocol for Studying Anterior Cruciate Ligament Reconstruction in a Rabbit Model
Crispim, João F. , Paggi, Carlo Alberto , Dudakovic, Amel , Genechten, Wouter Van , Hewett, Timothy E. , Krych, Aaron J. , Wijnen, André J. van , Saris, Daniël B.F. , Paggi, Carlo A, van Genechten, Wouter, Hewett, Timothy, van Wijnen, Andre J , Krych, Aaron J , Hevesi, Mario , Kakar, Sanjeev

Mayo Clinic

Tissue Engineering Part C: Methods | March 19, 2019 | Volume: 25 | Issue: 4 | Pages: 191-196

10.1089/ten.tec.2018.0357 | PMID 30887885 Get It

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines
Chang, Susan M. , Messersmith, Hans , Ahluwalia, Manmeet S. , Gaspar, Laurie E., Gatson, Na Tosha , Khasraw, Mustafa , Lassman, Andrew B. , Maués, Julia , Mrugała, Maciej M. , Raizer, Jeffrey J. , Schiff, David , Stevens, Glen , Sumrall, Ashley , Bent, Martin J. van den , Vogelbaum, Michael A. , van den Bent, Martin J , Khasraw, Mustafa , Gatson, Na Tosha N , Messersmith, Hans , Sumrall, Ashley , Ahluwalia, Manmeet S , Chang, Susan Marina , Andrews, David William , Brastianos, Priscilla K. , Jordan, Justin T.

Mayo Clinic

Journal of Clinical Oncology | March 18, 2019 | Volume: 37 | Issue: 13 | Pages: 1130-1135

10.1200/jco.18.02085 | PMID 30883246 Get It

PURPOSE The Congress of Neurological Surgeons (CNS) has developed a series of guidelines for the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS Two CNS guidelines were reviewed for developmental rigor by methodologists, and an independent multidisciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. The Expert Panel voted to endorse the two guidelines, and ASCO and Society for Neuro-Oncology (SNO) independently reviewed and approved the ASCO/SNO guideline endorsement. RESULTS The ASCO/SNO Expert Panel determined that the recommendations from the CNS anticonvulsants and steroids guidelines, published January 9, 2019, are clear, thorough, and based on the most relevant scientific evidence. ASCO/SNO endorsed these two CNS guidelines with minor alterations. RECOMMENDATIONS Key recommendations include the following: prophylactic antiepileptic drugs were not recommended for routine use; and corticosteroids, specifically dexamethasone, were recommended for temporary symptomatic relief in patients with neurologic symptoms and signs related to mass effect from brain metastases. Additional information is available at www.asco.org/neurooncology-guidelines .
Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)
Kiely, David G. , Levin, David L. , Ivy, D. Dunbar , Bwika, Jumaa, Lordan, Jim , Mazurek, Jeremy A. , Moledina, Shahin , Olschewski, Horst , Peacock, Andrew J. , Puri, G. D., Rahaghi, Farbod N. , Schäfer, Michal , Screaton, Nicholas, Noordegraaf, Anton Vonk , Vandepool, Rebecca, Wort, Stephen J. , Zhao, Lan , Wild, Jim M. , Vogel‐Claussen, Jens , Swift, Andrew J. , Vanderpool, Rebecca , Levin, David, Olschewski, Horst , Vonk Noordegraaf, Anton , Vanderpool, Rebecca R , Wild, Jim M , Hassoun, Paul M. , Jone, Pei-Ni , Kawut, Steven M. , Lungu, Angela , Schiebler, Mark , Tawhai, Merryn Howatson , Beek, Edwin J.R. van , Kiely, David , Vogel-Claussen, Jens

Mayo Clinic

Pulmonary Circulation | March 18, 2019 | Volume: 9 | Issue: 3 | Pages: 1-32

10.1177/2045894019841990 | PMID 30880632 Get It

Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life‐shortening condition. There have been significant advances in imaging technologies, but despite evidence of their potential clinical utility, practice remains variable, dependent in part on imaging availability and expertise. This statement summarizes current and emerging imaging modalities and their potential role in the diagnosis and assessment of suspected PH. It also includes a review of commonly encountered clinical and radiological scenarios, and imaging and modeling‐based biomarkers. An expert panel was formed including clinicians, radiologists, imaging scientists, and computational modelers. Section editors generated a series of summary statements based on a review of the literature and professional experience and, following consensus review, a diagnostic algorithm and 55 statements were agreed. The diagnostic algorithm and summary statements emphasize the key role and added value of imaging in the diagnosis and assessment of PH and highlight areas requiring further research.
Epidemiology of Shock in Contemporary Cardiac Intensive Care Units
Berg, David D. , Bohula, Erin A. , Katz, Jason N. , Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Burke, James A. , Cremer, Paul , Cruz, Jennifer , Daniels, Lori B. , DeFilippis, Andrew P. , Haleem, Affan , Hollenberg, Steven M. , Horowitz, James M. , Keller, Norma, Kontos, Michael C. , Lawler, Patrick R. , Menon, Venu , Metkus, Thomas S. , Ng, Jason, Orgel, Ryan, Overgaard, Christopher B., Park, Jeong-Gun, Phreaner, Nicholas , Roswell, Robert O. , Schulman, Steven P. , Snell, R. Jeffrey, Solomon, Michael A. , Ternus, Bradley , Tymchak, Wayne , Vikram, Fnu, Morrow, David A. , Lawler, Patrick , Solomon, Michael A , Morrow, David A , Roswell, Robert O , Daniels, Lori B , Bohula, Erin A , Cremer, Paul C , Berg, David , Diepen, Sean van , Barnett, Christopher F. , Burke, James A., Park, Jeong‐Gun

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 16, 2019 | Volume: 12 | Issue: 3 | Pages: No page available

10.1161/circoutcomes.119.005618 | PMID 30879324 Get It

Background Clinical investigations of shock in cardiac intensive care units (CICUs) have primarily focused on acute myocardial infarction (AMI) complicated by cardiogenic shock (AMICS). Few studies have evaluated the full spectrum of shock in contemporary CICUs. Methods and Results The Critical Care Cardiology Trials Network is a multicenter network of advanced CICUs in North America. Anytime between September 2017 and September 2018, each center (n=16) contributed a 2-month snap-shot of all consecutive medical admissions to the CICU. Data were submitted to the central coordinating center (TIMI Study Group, Boston, MA). Shock was defined as sustained systolic blood pressure <90 mm Hg with end-organ dysfunction ascribed to the hypotension. Shock type was classified by site investigators as cardiogenic, distributive, hypovolemic, or mixed. Among 3049 CICU admissions, 677 (22%) met clinical criteria for shock. Shock type was varied, with 66% assessed as cardiogenic shock (CS), 7% as distributive, 3% as hypovolemic, 20% as mixed, and 4% as unknown. Among patients with CS (n=450), 30% had AMICS, 18% had ischemic cardiomyopathy without AMI, 28% had nonischemic cardiomyopathy, and 17% had a cardiac cause other than primary myocardial dysfunction. Patients with mixed shock had cardiovascular comorbidities similar to patients with CS. The median CICU stay was 4.0 days (interquartile range [IQR], 2.5–8.1 days) for AMICS, 4.3 days (IQR, 2.1–8.5 days) for CS not related to AMI, and 5.8 days (IQR, 2.9–10.0 days) for mixed shock versus 1.9 days (IQR, 1.0–3.6) for patients without shock ( P <0.01 for each). Median Sequential Organ Failure Assessment scores were higher in patients with mixed shock (10; IQR, 6–13) versus AMICS (8; IQR, 5–11) or CS without AMI (7; IQR, 5–11; each P <0.01). In-hospital mortality rates were 36% (95% CI, 28%–45%), 31% (95% CI, 26%–36%), and 39% (95% CI, 31%–48%) in AMICS, CS without AMI, and mixed shock, respectively. Conclusions The epidemiology of shock in contemporary advanced CICUs is varied, and AMICS now represents less than one-third of all CS. Despite advanced therapies, mortality in CS and mixed shock remains high. Investigation of management strategies and new therapies to treat shock in the CICU should take this epidemiology into account.
Role of Critical Care Medicine Training in the Cardiovascular Intensive Care Unit: Survey Responses From Dual Certified Critical Care Cardiologists
Brusca, Samuel B. , Barnett, Christopher F. , Barnhart, Brendan J. , Weng, Weifeng , Soble, Jeffrey S., Katz, Jason N. , Wiley, Brandon M. , Gomez, A.D., Solomon, Michael A. , Solomon, Michael A , Morrow, David A. , Diepen, Sean van

Mayo Clinic

Journal of the American Heart Association | March 16, 2019 | Volume: 8 | Issue: 6 | Pages: No page available

10.1161/jaha.118.011721 | PMID 30879373 Get It

Background Cardiovascular intensive care units ( CICUs ) have evolved from coronary care wards into distinct units for critically ill patients with primary cardiac diseases, often suffering from illnesses that cross multiple disciplines. Mounting evidence has demonstrated improved survival with the incorporation of dedicated CICU providers with expertise in critical care medicine ( CCM ). This is the first study to systematically survey dual certified physicians in order to assess the relevance of CCM training to contemporary CICU care. Methods and Results Utilizing American Board of Internal Medicine data through 2014, 397 eligible physicians had obtained initial certification in both cardiovascular disease and CCM . A survey to delineate the role of critical care training in the CICU was provided to these physicians. Among those surveyed, 120 physicians (30%) responded. Dual certified physicians reported frequent use of their CCM skills in the CICU , highlighting ventilator management, multiorgan dysfunction management, end‐of‐life care, and airway management. The majority (85%) cited these skills as the reason CCM training should be prioritized by future CICU providers. Few (17%) agreed that general cardiology fellowship alone is currently sufficient to care for patients in the modern CICU . Furthermore, there was a consensus that there is an unmet need for cardiologists trained in CCM (70%) and that CICU s should adopt a level system similar to trauma centers (61%). Conclusions Citing specific skills acquired during CCM training, dual certified critical care cardiologists reported that their additional critical care experience was necessary in their practice to effectively deliver care in the modern CICU .
Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer
Fritz, Andrew J. , Gerrard, Diana L., Hong, David I. , Rose, Joshua T., Ghule, Prachi N. , Bolf, Eric L. , Gordon, Jonathan , Tracy, Kirsten M. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Heath, Jessica L. , Frietze, Seth , Zaidi, Sayyed K. , Carr, Frances E. , Lian, Jane B. , Stein, Janet L. , Fritz, A J , Stein, Gary S , van Wijnen, Andre J , Tracy, Kirsten M , Gillis, Noelle E. , Rodriguez, Princess D. , Hong, D., Gordon, J.A., Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Genes, Chromosomes and Cancer | March 15, 2019 | Volume: 58 | Issue: 7 | Pages: 484-499

10.1002/gcc.22731 | PMID 30873710 Get It

Cells establish and sustain structural and functional integrity of the genome to support cellular identity and prevent malignant transformation. In this review, we present a strategic overview of epigenetic regulatory mechanisms including histone modifications and higher order chromatin organization (HCO) that are perturbed in breast cancer onset and progression. Implications for dysfunctions that occur in hormone regulation, cell cycle control, and mitotic bookmarking in breast cancer are considered, with an emphasis on epithelial‐to‐mesenchymal transition and cancer stem cell activities. The architectural organization of regulatory machinery is addressed within the contexts of translating cancer‐compromised genomic organization to advances in breast cancer risk assessment, diagnosis, prognosis, and identification of novel therapeutic targets with high specificity and minimal off target effects.